TipRanks
Beam Therapeutics (BEAM)
NASDAQ:BEAM
US Market
BEAM
Beam Therapeutics
RESEARCH TOOLSreports
Want to see BEAM full AI Analyst Report?

Beam Therapeutics (BEAM) Stock Forecast & Price Target

2,353 Followers
See the Price Targets and Ratings of:

BEAM Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Beam
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$53.73
▲(73.15% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $53.73 with a high forecast of $80.00 and a low forecast of $26.00. The average price target represents a 73.15% change from the last price of $31.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","52":"$52","81":"$81","37.5":"$37.5","66.5":"$66.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.72727272727273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,37.5,52,66.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.39,28.667692307692306,32.94538461538461,37.223076923076924,41.50076923076923,45.778461538461535,50.05615384615385,54.33384615384615,58.61153846153846,62.889230769230764,67.16692307692307,71.44461538461539,75.72230769230768,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.39,26.646713286713286,28.90342657342657,31.16013986013986,33.41685314685314,35.673566433566435,37.93027972027972,40.186993006993006,42.44370629370629,44.70041958041958,46.95713286713286,49.21384615384615,51.47055944055944,{"y":53.72727272727273,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.39,24.513846153846153,24.63769230769231,24.76153846153846,24.885384615384616,25.00923076923077,25.133076923076924,25.256923076923076,25.380769230769232,25.504615384615384,25.62846153846154,25.752307692307692,25.876153846153848,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.14,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.02,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.39,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$53.73Lowest Price Target$26.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$80
Buy
157.82%
Upside
Reiterated
10/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on BEAM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$65
Buy
109.47%
Upside
Reiterated
10/14/26
Wedbush Remains a Buy on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$78
Buy
151.37%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (NASDAQ: EWTX), Beam Therapeutics (NASDAQ: BEAM) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
Citi Analyst forecast on BEAM
Samantha Semenkow
Citi
Citi
$68
Buy
119.14%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Cogent Biosciences (NASDAQ: COGT) and InMode (NASDAQ: INMD)
Wells Fargo Analyst forecast on BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$70
Buy
125.59%
Upside
Reiterated
10/02/26
Wells Fargo Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
JonesTrading Analyst forecast on BEAM
Boris Peaker
JonesTrading
JonesTrading
$35
Buy
12.79%
Upside
Reiterated
09/09/26
JonesTrading Remains a Buy on Beam Therapeutics (BEAM)
Clear Street Analyst forecast on BEAM
Mara Goldstein
Clear Street
Clear Street
$37
Buy
19.24%
Upside
Reiterated
09/09/26
Beam Therapeutics (BEAM) Gets a Buy from Clear Street
William Blair Analyst forecast on BEAM
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback
Bank of America Securities Analyst forecast on BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$43
Buy
38.58%
Upside
Reiterated
09/08/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Beam Therapeutics (NASDAQ: BEAM) and Royalty Pharma (NASDAQ: RPRX)
J.P. Morgan Analyst forecast on BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
$44
Buy
41.80%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
Evercore ISI Analyst forecast on BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$45
Buy
45.02%
Upside
Reiterated
08/05/26
Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on BEAM
Luca Issi
RBC Capital
RBC Capital
$26
Hold
-16.21%
Downside
Reiterated
08/05/26
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Bernstein Analyst forecast on BEAM
William Pickering
Bernstein
Bernstein
$40→$39
Buy
25.68%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
UBS Analyst forecast on BEAM
Michael Yee
UBS
UBS
$28
Hold
-9.76%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on BEAM
Gena Wang
Barclays
Barclays
$21
Hold
-32.32%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$80
Buy
157.82%
Upside
Reiterated
10/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on BEAM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$65
Buy
109.47%
Upside
Reiterated
10/14/26
Wedbush Remains a Buy on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$78
Buy
151.37%
Upside
Reiterated
10/14/26
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (NASDAQ: EWTX), Beam Therapeutics (NASDAQ: BEAM) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
Citi Analyst forecast on BEAM
Samantha Semenkow
Citi
Citi
$68
Buy
119.14%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Cogent Biosciences (NASDAQ: COGT) and InMode (NASDAQ: INMD)
Wells Fargo Analyst forecast on BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$70
Buy
125.59%
Upside
Reiterated
10/02/26
Wells Fargo Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
JonesTrading Analyst forecast on BEAM
Boris Peaker
JonesTrading
JonesTrading
$35
Buy
12.79%
Upside
Reiterated
09/09/26
JonesTrading Remains a Buy on Beam Therapeutics (BEAM)
Clear Street Analyst forecast on BEAM
Mara Goldstein
Clear Street
Clear Street
$37
Buy
19.24%
Upside
Reiterated
09/09/26
Beam Therapeutics (BEAM) Gets a Buy from Clear Street
William Blair Analyst forecast on BEAM
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback
Bank of America Securities Analyst forecast on BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$43
Buy
38.58%
Upside
Reiterated
09/08/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Beam Therapeutics (NASDAQ: BEAM) and Royalty Pharma (NASDAQ: RPRX)
J.P. Morgan Analyst forecast on BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
$44
Buy
41.80%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
Evercore ISI Analyst forecast on BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$45
Buy
45.02%
Upside
Reiterated
08/05/26
Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on BEAM
Luca Issi
RBC Capital
RBC Capital
$26
Hold
-16.21%
Downside
Reiterated
08/05/26
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Bernstein Analyst forecast on BEAM
William Pickering
Bernstein
Bernstein
$40→$39
Buy
25.68%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
UBS Analyst forecast on BEAM
Michael Yee
UBS
UBS
$28
Hold
-9.76%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on BEAM
Gena Wang
Barclays
Barclays
$21
Hold
-32.32%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
OVIDOvid Therapeutics
OMCLOmnicell
IMUXImmunic
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
12/20 ratings generated profit
60%
Average Return
+0.97%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +0.97% per trade.
1 Year
Yanan ZhuWells Fargo
Success Rate
10/22 ratings generated profit
45%
Average Return
+1.35%
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +1.35% per trade.
2 Years
Alec StranahanBank of America Securities
Success Rate
7/16 ratings generated profit
44%
Average Return
+2.05%
Copying Alec Stranahan's trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of +2.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
9
11
13
17
Buy
6
6
4
7
6
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
16
16
21
24
In the current month, BEAM has received 23 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 53.73.
Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$1.15 with a range of -$1.28 to -$1.00. The previous quarter’s EPS was -$1.18. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s earnings estimate for BEAM is -$1.15 with a range of -$1.28 to -$1.00. The previous quarter’s EPS was -$1.18. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $8.75M with a range of $0.00 to $31.74M. The previous quarter’s sales results were $490.00K. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s sales forecast for BEAM is $8.75M with a range of $0.00 to $31.74M. The previous quarter’s sales results were $490.00K. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Stock Forecast FAQ

What is BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 53.73.
    What is BEAM’s upside potential, based on the analysts’ average price target?
    Beam Therapeutics has 73.15% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BEAM a Buy, Sell or Hold?
          Beam Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Beam Therapeutics’s price target?
            The average price target for Beam Therapeutics is 53.73. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $80.00 ,the lowest forecast is $26.00. The average price target represents 73.15% Increase from the current price of $31.03.
              What do analysts say about Beam Therapeutics?
              Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BEAM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.